🇺🇸

Regulatory Compliance

· daily

US SEC Trading Suspension Halt Orders — April 10, 2026

A cluster of six Nasdaq-listed microcap companies received deficiency notices on April 7, 2026, primarily for failing the $1.00 minimum bid price requirement over 30 consecutive business days (Feb 23-Apr 6, 2026) or stockholders' equity below $2.5M as of Dec 31, 2025, signaling acute delisting risks across emerging growth firms. Four filings highlight bid price non-compliance, with three ineligible for standard 180-day extensions due to prior reverse stock splits (DevvStream, Beyond Air, SCWorx), while two face equity shortfalls (Caring Brands at $2.09M vs $2.5M req., Callan JMB below $2.5M). No positive period-over-period financial trends evident; persistent sub-$1 bids reflect YoY/QoQ share price deterioration amid weak fundamentals. SCWorx faces imminent trading suspension on April 14 post failed 180-day extension from 2025 notice. Portfolio implications include heightened volatility, potential OTC delistings, and liquidity evaporation for small-cap holders; no bullish insider activity or capital returns noted, all sentiments negative with high materiality (9-10/10).

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — April 09, 2026

A cluster of 5 Nasdaq-related regulatory actions highlights acute distress among small-cap US-listed companies, with Actelis Networks facing immediate delisting on April 10, 2026, after a failed 1-for-10 reverse split on November 18, 2025, marking the most severe outcome. Three companies (Gossamer Bio, FibroGen, Newton Golf) received deficiency notices for bid price, assets/revenue, and stockholders' equity failures, respectively, with 45-180 day compliance windows through October 2026, while Beyond Meat resolved a late 10-K filing without disruption. No enriched period-over-period financial trends show growth; instead, implied YoY deteriorations (e.g., FibroGen revenue shifted to discontinued ops for 2024-2025) underscore weak fundamentals driving non-compliance. Biotech firms (Gossamer, FibroGen) represent 40% of cases, signaling sector-specific pressures amid low bid prices and asset shortfalls. Portfolio-level implications include liquidity erosion, OTC transitions, and heightened short opportunities, with no bullish capital allocation or insider buying patterns evident across filings.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — April 08, 2026

The USA Trading Suspensions stream features one key filing from SPAR Group, Inc. (SGRP), highlighting acute Nasdaq compliance failure with stockholders’ equity at just $622,000 as of December 31, 2025, versus the required $2.5 million minimum, alongside failures in alternative criteria of $35 million market value or $500,000 net income. No period-over-period comparisons available in the filing, but the equity deficiency signals ongoing financial deterioration into YE 2025 from prior 10-K data. This represents a 10/10 materiality event with negative sentiment, posing immediate delisting risk on Nasdaq Capital Market. Portfolio-level trends are limited to this single instance in a very quiet session, but it underscores small-cap vulnerability to regulatory halts. Market implications include potential trading suspension, heightened volatility, and forced liquidation pressures for holders. No bullish offsets from insider activity, capital allocation, or forward guidance noted.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — April 07, 2026

Across five small-cap filings in the USA Trading Suspensions stream, a dominant theme is Nasdaq non-compliance with Listing Rule 5550(b)(1) due to severe stockholders’ equity deficits (HYFM -$63.3M, Direct Digital -$7.0M as of Dec 31, 2025), alongside bid price issues (Tianci resolved), NYSE filing delays (Genie), and voluntary delisting (WM Technology). Negative sentiment prevails in 4/5 cases (materiality 9-10/10), signaling heightened delisting risks and potential trading halts, with no period-over-period financial improvements noted to reverse deficits QoQ into Q1 2026. Forward-looking catalysts cluster in April-May 2026, including compliance plans (HYFM May 16), hearings (Direct Digital by Apr 9), and delisting (WM ~Apr 24), implying immediate liquidity erosion on US exchanges. No insider trading activity reported across filings, but persistent deficits vs required $2.5M minimum highlight capital allocation failures and operational distress. Portfolio-level pattern: 80% of companies face imminent regulatory cliffs, favoring short/avoid strategies for Nasdaq small caps amid no YoY equity recovery trends.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — April 03, 2026

A cluster of five micro-cap companies across tech, AI, biotech, and marine sectors received delisting deficiency notices from Nasdaq and NYSE American between March 31 and April 2, 2026, signaling acute listing compliance pressures amid sustained low bid prices, equity shortfalls, and market value deficiencies. Common themes include bid price failures below $1 for 30 consecutive business days (e.g., Twin Vee post-1-for-10 reverse split in April 2025), stockholders' equity deficits (Matinas at $4.83M below $2M-$6M thresholds with 5-year losses; AEON at -$55M deficit with losses in 3/4 years), and MVPHS/MVLS shortfalls (Arrive AI below $15M/$50M). No positive period-over-period financial trends evident; instead, prolonged deficiencies (e.g., Aeries initial notice September 2025) indicate deteriorating compliance trajectories with no YoY equity recovery or bid price stabilization. All firms plan appeals or compliance plans, but ineligibility for extensions (e.g., Twin Vee, Aeries) heightens delisting risks, potentially leading to trading halts, OTC transfers, and shareholder value erosion. Portfolio-level pattern: 5/5 companies show negative sentiment (4/5 outright negative, 1 mixed), with biotechs overrepresented in equity failures; investors face liquidity risks in small caps. Critical implication: Imminent catalyst calendar of hearings and plans could trigger suspensions, advising avoidance or short positioning.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — April 02, 2026

Across five US-listed small-cap companies, a cluster of Nasdaq and NYSE listing compliance failures emerged in late March-early April 2026, primarily driven by sub-$1.00 bid prices (3/5 filings), low market value of listed securities (1/5), governance issues (1/5), and insufficient market cap (1/5), signaling broad small-cap distress amid low valuations. No period-over-period financial trends like revenue growth or margins are detailed, but prior non-compliance periods (e.g., CytoSorbents' initial 180 days ending March 31, 2026) highlight persistent deterioration in stock price and market value metrics over 30-180 day windows. Most receive 180-day compliance extensions to September 2026 with no immediate delisting, except Solo Brands facing NYSE delisting proceedings starting April 2, 2026, and OTC transition. Sentiments skew negative/mixed (3 negative, 2 mixed), with high materiality (avg 9/10), implying elevated delisting risks, potential reverse splits, and liquidity erosion. Portfolio-level pattern: 4/5 emerging growth companies, concentrated Nasdaq issues (80%), pointing to sector-wide undervaluation or operational challenges in biotech/tech/consumer spaces. Market implications include heightened volatility, OTC trading discounts, and short-term trading opportunities around appeals/compliance catalysts.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — April 01, 2026

The intelligence stream on USA Trading Suspensions reveals a single high-materiality (9/10) event for The Brand House Collective, Inc. (TBHC), flagged with a Nasdaq deficiency notice on March 26, 2026, for MVPHS below $15M for 30 consecutive business days, breaching Listing Rule 5450(b)(3)(C). No immediate trading halt occurred, but delisting risk looms if compliance isn't regained by September 22, 2026, via $15M MVPHS for 10 consecutive days. A pending merger with Bed Bath & Beyond, Inc. (announced November 24, 2025) is expected to close beforehand, triggering voluntary delisting as TBHC becomes a wholly owned subsidiary, with the parent's common stock remaining NYSE-listed. No period-over-period financial trends, insider activity, capital allocation details, or operational metrics were enriched in the filing, limiting quantitative comparisons, but negative sentiment dominates due to compliance uncertainty. This isolated case underscores small-cap liquidity vulnerabilities on Nasdaq, with merger as a potential resolution catalyst. Investors face heightened volatility risks ahead of the compliance deadline.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — March 31, 2026

Across four US exchange filings in the trading suspensions stream, a split emerges with two companies (Classover Holdings and USBC, Inc.) regaining compliance and two facing severe challenges (Iterum Therapeutics delisting and Snail, Inc. deficiency notice), highlighting volatility in micro-cap listing standards amid economic pressures. Key period-over-period trends show inconsistent profitability, exemplified by Snail's net income in 2024 contrasting losses in 2023 (-ve) and 2025 (-ve), signaling erratic financial health without YoY revenue or margin data available. Critical developments include Iterum's imminent Nasdaq delisting and suspension on April 1, 2026, due to bid price failure and Irish winding-up petition, posing total illiquidity risk, while compliance regains boost short-term stability for KIDZ and USBC. Portfolio-level patterns reveal 2/4 emerging growth companies navigating Nasdaq/NYSE American rules, with positive resolutions outpacing negatives but high materiality (avg 8.5/10) underscoring time-sensitive risks. Market implications favor short positions on delisting candidates and monitoring turnaround catalysts, as no insider activity or capital allocation shifts were noted across filings.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — March 30, 2026

Across 7 US-listed companies facing trading suspensions or delisting risks in late March 2026, themes center on Nasdaq $1 minimum bid price violations (4/7 filings), financial metric deficiencies (2/7), and one voluntary delist post-SPAC merger, highlighting small-cap liquidity and compliance struggles. Positive resolutions emerged in Vine Hill Capital's 92.6% merger approval leading to relisting as Odysseus, Sky Quarry's post-reverse-split compliance regain, and Triller's conditional reinstatement path, contrasting with ongoing risks for Dyadic, Greenlane, InMed, and Skillsoft. No explicit YoY/QoQ financial trends available, but repeated non-compliance periods (e.g., Sky Quarry's two 180-day extensions expiring Sep 2025/Mar 2026) signal deteriorating bid prices over 12+ months. Mixed sentiment prevails (3 negative, 2 mixed, 1 positive, 1 negative on NYSE), with materiality high (8-10/10), implying imminent trading halts or delistings for non-compliant firms, pressuring valuations and liquidity. Portfolio-level pattern: reverse splits in 3/7 (Sky Quarry 1:8, Greenlane cumulative 1:8250) as desperate compliance tools, often failing long-term. Market implication: short-term volatility spikes around Mar 31 deadlines, potential OTC trading shifts reducing institutional access.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — March 27, 2026

A cluster of 7 small-cap US-listed companies disclosed Nasdaq or NYSE deficiency notices dated March 24-27, 2026, primarily for bid prices below $1.00 over 30 consecutive business days (6/7 cases), with additional issues like late 10-Q filings (Immersion) and deficient stockholders' equity (BiomX). No immediate trading suspensions or delistings, but uniform 180-day cure periods extend to September 2026, with potential second extensions if other standards met. Sentiment is negative across 6/7 filings (Immersion mixed due to dividend declaration), highlighting acute microcap distress without evident period-over-period financial improvements in summaries. Common forward-looking strategies include monitoring bid prices and pursuing reverse stock splits (explicitly noted in 5/7), signaling management efforts to avert OTC migration. Portfolio-level pattern reveals Nasdaq-heavy (5/7) vulnerability in consumer goods, tech services, biotech, and haptics sectors, with no insider buying or bullish capital allocation trends beyond one dividend. Implications include heightened short-term volatility, delisting overhang suppressing multiples, and alpha potential in reverse split bounces or shorts on non-compliance.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — March 26, 2026

Two US-listed companies, FiscalNote Holdings (NOTE) and Cambium Networks (CMBM), faced delisting notices on March 25, 2026, triggering immediate or imminent trading suspensions due to failure to meet exchange listing rules—low average share price for NOTE (below $1.00 over 30 trading days) and non-compliance with prior Nasdaq decision for CMBM. Trading for NOTE (common and warrants NOTE.WS) suspended immediately on NYSE, shifting to OTC Markets on March 26, 2026; CMBM suspension effective March 27 open on Nasdaq, moving to OTCID. No enriched period-over-period financial trends, insider activity, capital allocation, or forward-looking guidance provided in filings, limiting quantitative comparisons, but both exhibit negative sentiment (10/10 materiality) with potential material adverse effects on share price and liquidity. Overarching theme: heightened regulatory pressure on low-priced small-cap stocks, signaling portfolio-level risks in compliance-challenged names. Investors face immediate liquidity and valuation risks, with appeals possible but uncertain outcomes; no impact on operations or SEC reporting noted.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — March 25, 2026

A cluster of 4 out of 5 small-cap companies (SOBR Safe, Longeveron, MAINZ Biomed, SelectQuote) received Nasdaq or NYSE deficiency notices in mid-March 2026 for failing the $1.00 minimum bid price requirement over 30 consecutive business/trading days, signaling acute valuation pressure and delisting risks across microcaps and biotechs with no reported financial metrics to counter the weakness. SOBR Safe stands out with a history of aggressive reverse splits (cumulative 1-for-1100 since 2024), rendering it ineligible for the standard 180-day compliance period and forcing an appeal process. Longeveron secured an extension to September 21, 2026, while MAINZ and SelectQuote have until mid-September 2026 to cure via potential reverse splits or price recovery. Trade Desk provides a stark positive outlier with the March 25 board appointment of Reddit CFO Drew Vollero, highlighting management strengthening amid high-growth ad tech resilience. No immediate trading suspensions or delistings, but portfolio-level trends show chronic stock price deterioration (all deficient periods Feb-Mar 2026), with high materiality (9/10) negative sentiment dominating; investors face heightened volatility and potential OTC downgrades by Q3 2026.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — March 24, 2026

Both BNB Plus Corp. and SurgePays, Inc. disclosed Nasdaq notifications for failing minimum listing standards, signaling acute delisting risks on the Nasdaq Capital Market amid chronically low bid prices below $1.00. BNB Plus is ineligible for a standard compliance period due to prior reverse stock splits totaling a 250:1 ratio over the past two years, while SurgePays has 180 calendar days to cure MVLS ($35M) and bid price deficiencies but faces immediate dilution from issuing 800,000 shares to CEO Brian Cox at $1.25/share to settle a $1M promissory note. No positive period-over-period financial trends evident; implied QoQ stock price deterioration with BNBX bid < $1 for 30 consecutive days (Feb 5-Mar 19, 2026) and SurgePays similarly deficient. Cross-filing pattern reveals 2/2 companies at Materiality 9/10 negative sentiment, highlighting systemic small-cap distress on Nasdaq. Forward-looking catalysts include BNB's planned hearing request and SurgePays' compliance deadlines in September 2026, but no assurance of listing retention. Portfolio-level implication: Heightened volatility and liquidity risks for Nasdaq small caps, urging avoidance or short strategies.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — March 23, 2026

Across the single filing in the USA Trading Suspensions stream, Volato Group, Inc. (SOAR) faces severe NYSE American delisting risk due to stockholders’ equity falling below $2.0M (losses in two of three recent fiscal years) and $4.0M (losses in three of four recent fiscal years), signaling prolonged financial distress with no provided YoY/QoQ recovery trends. Negative sentiment dominates with 9/10 materiality, highlighting non-compliance under Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide. No immediate trading suspension impacts Class A Common Stock (SOAR) on NYSE American, but warrants (SOARW) already trade on OTC Markets, foreshadowing potential further liquidity erosion. Absent enriched data on insider activity shows no management buying conviction, while forward-looking compliance deadlines (plan by April 16, 2026; regain standards by December 17, 2026) create a high-stakes catalyst calendar. Capital allocation details unavailable, but sustained losses imply strained shareholder returns with no dividends or buybacks noted. Portfolio-level theme: isolated small-cap aviation player exemplifies regulatory vulnerability amid equity deficits, urging immediate position reviews.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — March 20, 2026

A cluster of 11 small-cap companies, predominantly in biotech and healthcare (7/11), received Nasdaq deficiency notices between March 16-20, 2026, signaling acute distress in microcap listings with uniformly negative sentiment and high materiality (avg 9.3/10). Dominant theme: 9/11 failed minimum bid price requirement (<$1.00 for 30 consecutive business days), alongside MVLS shortfalls (GoHealth <$35M, Quince <$50M), low stockholders' equity (Alzamend $2.2M vs $2.5M min), and one audit committee violation (Lifeward <3 members). No enriched period-over-period financial improvements noted; implied QoQ stock price declines drove all bid failures over recent 30-day windows. Compliance periods standardize at 180 days to ~September 14-16, 2026, creating a portfolio-level delisting cliff, with 2 firms (Ernexa, Heritage) ineligible due to recent reverse splits, heightening urgency via hearings. Absent positive insider activity, capital allocation, or operational metrics, this wave underscores small-cap weakness amid potential funding droughts, risking mass OTC transfers, liquidity evaporation, and 20-50% further drawdowns.

11 high priority 11 total filings
· daily

US SEC Trading Suspension Halt Orders — March 19, 2026

Three US-listed companies—AVAX One Technology Ltd. (Nasdaq), Skye Bioscience, Inc. (Nasdaq), and Getty Images Holdings, Inc. (NYSE)—received deficiency notices between March 13-17, 2026, for common stock bid/closing prices below $1.00 for 30 consecutive business/trading days, violating Nasdaq Listing Rules 5550(a)(2)/5450(a)(1) and NYSE Section 802.01C. This represents a uniform 30-day period-over-period price decline trend across all filings, signaling broad weakness in share prices with no YoY/QoQ recovery mentioned. No immediate trading suspensions occurred, but high materiality (9/10) and negative sentiment underscore delisting risks, with AVAX securing a hearing stay, Skye gaining 180 calendar days to September 14, 2026, and Getty a six-month cure period. Forward-looking paths include potential reverse stock splits (explicit for Skye, implied elsewhere) and compliance via 10 consecutive days at or above $1.00, though no assurances provided. Portfolio-level pattern: cross-sector small-cap distress (tech, biotech, media), amplifying volatility and potential OTC transfers. Implications include heightened short interest, dilution risks from splits, and time-sensitive catalysts for investor positioning.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — March 18, 2026

Both CalciMedica, Inc. (CALC) and Glimpse Group, Inc. (GGRP) received Nasdaq deficiency notices on March 13-16, 2026, primarily for failing the minimum bid price requirement (closing below $1.00/share for 30 consecutive business days), with CALC additionally cited for MVLS below $35M, stockholders' equity, and net income standards under Rules 5550(b)(1)/(3). No period-over-period financial trends are detailed in filings, but implied weak performance (low MVLS/equity/net income) signals deteriorating fundamentals amid small-cap pressures. Trading remains uninterrupted for both, providing 180 calendar days to regain compliance by September 9-14, 2026, via measures like reverse stock splits, though success is uncertain. Negative sentiment across filings (materiality 9/10) underscores heightened delisting risks, with no reported insider activity, capital allocation changes, or forward guidance to counter bearish outlook. Portfolio-level pattern: 2/2 companies in Nasdaq Capital Market face simultaneous compliance threats, highlighting microcap vulnerability in biotech (CALC) and emerging tech (GGRP) sectors. Implications include potential volatility from reverse splits or delistings, urging avoidance or short strategies.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — March 17, 2026

Nasdaq listing compliance challenges dominate the USA Trading Suspensions stream, with Urgent.ly Inc. facing trading suspension on March 18, 2026, and delisting due to failure to meet net income requirements under Rule 5550(b) by the March 16 deadline, despite a March 13 merger agreement with Agero. Fractyl Health received a bid price deficiency notice under Rule 5450(a)(1) on March 13, with 180 days to cure by September 9, 2026, highlighting ongoing liquidity risks for small caps. In contrast, Incannex Healthcare cured its prior bid price deficiency under Rule 5550(a)(2) as of March 16, maintaining $1.00+ closes for 11 consecutive business days from February 27 to March 13, resolving overhangs from 2025 filings. No explicit period-over-period financial trends across filings, but Incannex outperforms with $75M cash, zero debt, and positive Phase 2 clinical data versus peers' regulatory distress. Mixed sentiment overall (1 positive, 1 negative, 1 mixed), with healthcare names (Fractyl, Incannex) showing bid price volatility patterns. Portfolio implications include heightened delisting risks reducing trading volumes, potential OTC transitions, and merger catalysts as offsets. Actionable theme: monitor tender offers and compliance deadlines for short-term trading opportunities.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — March 16, 2026

Across the two filings in the USA Trading Suspensions stream, both Lyra Therapeutics (LYRA) and Greenland Technologies Holding Corp. (GTEC) face critical Nasdaq delisting risks, highlighting a pattern of small-cap compliance failures on the Nasdaq Capital Market. LYRA's withdrawal of its delisting appeal confirms trading suspension at the open on March 17, 2026, following a February 2, 2026 determination, marking an immediate negative milestone with no positive offsets. GTEC violated Listing Rule 5550(a)(2) with Class A shares closing below $1.00 for 30 consecutive business days from January 28 to March 11, 2026, but has a 180-day compliance window until September 8, 2026. No period-over-period financial trends, insider trading activity, capital allocation changes, or forward-looking guidance beyond compliance plans are disclosed, focusing attention solely on regulatory halts. Market implications include heightened illiquidity risks for LYRA shareholders and monitoring needs for GTEC's potential reverse split or cure. Portfolio-level theme: 2/2 companies exhibit deteriorating listing compliance with negative sentiment (materiality 9-10/10), signaling caution for Nasdaq small-caps amid bid price pressures.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — March 13, 2026

Four small-cap companies across healthcare and biotech sectors reported critical US exchange listing compliance failures in March 2026, highlighting a portfolio-level trend of microcap distress with 3/4 filings showing negative sentiment and persistent financial weaknesses like low bid prices, equity deficiencies, and MVPHS shortfalls. No positive YoY/QoQ revenue or margin trends evident; instead, Azitra disclosed net losses across five consecutive fiscal years ended Dec 31, 2025, with stockholders' equity at $3.8M versus $6.0M required, signaling ongoing deterioration from prior $4.0M deficiency. Bio Green Med faces imminent preferred stock delisting and trading suspension on Mar 23, 2026, post-180-day compliance failure from Sep 11, 2025 notice, while Talphera's bid price < $1.00 for 30 days triggers 180-day clock to Sep 7, 2026. Sadot Group resolved a voting rights violation via amendment, marking the sole mixed-positive outcome. Market implications include elevated delisting risks, potential reverse splits, OTC migrations, and short-term price volatility, with no insider buying or dividend hikes to signal conviction—watch for cascading suspensions in weak microcaps.

4 high priority 4 total filings